Showing results (61-70 of 176) with videos related to
Sort By:
Pageof 18
Biomarker Research|July 2, 2020
Clinical characteristics and prognostic value of the <i>KRAS G12C</i> mutation in Chinese non-small cell lung cancer patientsSi-Yang Liu, Hao Sun, Jia-Ying Zhou, et al.Clinical Lung Cancer|July 22, 2014
Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancerYan-yan He, Xu-chao Zhang, Jin-ji Yang, et al.Translational Lung Cancer Research|November 7, 2024
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired <i>BRAF</i> V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced <i>EGFR</i>-mutated non-small cell lung cancer patientsCheng-Di Weng, Ke-Jun Liu, Shi Jin, et al.Chinese Journal of Cancer|June 29, 2017
Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patientsHao-Ran Zhai, Xue-Ning Yang, Qiang Nie, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.Medical Oncology (Northwood, London, England)|April 5, 2011
Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapyShe-Juan An, Yi-Sheng Huang, Zhi-Hong Chen, et al.The International Journal of Biological Markers|March 7, 2015
Single nucleotide polymorphisms in VTI1A gene contribute to the susceptibility of Chinese population to non-small cell lung cancerWen-Mei Su, Zhi-Hong Chen, Xu-Chao Zhang, et al.Journal of Thoracic Disease|November 12, 2015
Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosisWen-Zhao Zhong, Wei Li, Xue-Ning Yang, et al.European Journal of Cancer (Oxford, England : 1990)|February 11, 2019
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)Zhen Wang, Cheng Huang, Jin-Ji Yang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2017
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858RE-E Ke, Qing Zhou, Qiu-Yi Zhang, et al.Pageof 18